The biopharma world kicks off each year with a frenzy of activity at JP Morgan. Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D.
Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.
Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.
Endpoints News and Chris Dokomajilar at DealForma are back with our annual breakdown of the top 100 VCs in biotech — a field that has undergone some dramatic changes in the past 5 years. Who’s a player? Who’s on the sidelines looking to jump in? Endpoints founder John Carroll will also host a webinar looking at a fascinating piece of the funding scene in the industry.
Endpoints News and Chris Dokomajilar at DealForma are back with our annual breakdown of the top 100 VCs in biotech — a field that has undergone some dramatic changes in the past 5 years. Who’s a player? Who’s on the sidelines looking to jump in? Endpoints founder John Carroll will host a webinar looking at a fascinating piece of the funding scene in the industry.
A list of drugs in development with the biggest launch potential
A list of 10 high-profile mistakes in the industry, examined and analyzed
Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts, or cloud all their efforts.
Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts, or cloud all their efforts.
Exclusive insights from a group of hand-picked biotech CEOs and A-list investors, and more
Recent human data has helped encourage a new brand of biotech out to use modified psychedelics to rewire the brain in search of new and better therapies for mental health. Once a marginalized, if not simply criminalized, research field, these new companies are luring investors and inspiring a range of new clinical programs. And J&J has helped drive the work with a pioneering — and still highly controversial — drug approval for esketamine that has both created new regulatory precedents while spurring debate about the future of the field.
Recent human data has helped encourage a new brand of biotech out to use modified psychedelics to rewire the brain in search of new and better therapies for mental health. Once a marginalized, if not simply criminalized, research field, these new companies are luring investors and inspiring a range of new clinical programs. And J&J has helped drive the work with a pioneering — and still highly controversial — drug approval for esketamine that has both created new regulatory precedents while spurring debate about the future of the field.
Once again Endpoints News founder John Carroll will dissect how the top 15 R&D organizations in the world — ranked by research spends — are doing. Over the past 10 years there have been some major changes in these groups, as R&D chiefs evaluate where to get the biggest bang for their buck. What are the big challenges in 2022 for the top R&D chiefs? And who’s winning, or losing, the multibillion-dollar battle on ROI.
Once again Endpoints News founder John Carroll will dissect how the top 15 R&D organizations in the world — ranked by research spends — are doing. Over the past 10 years there have been some major changes in these groups, as R&D chiefs evaluate where to get the biggest bang for their buck. What are the big challenges in 2022 for the top R&D chiefs? And who’s winning, or losing, the multibillion-dollar battle on ROI.
In recent years we’ve seen biomarkers like ctDNA change the course of cancer studies, offering a shortcut to the market while offering a much clearer picture of what patient subgroups are likely to benefit from the slew of experimental therapies in the clinic. What new biomarkers are being hatched today? And what impact will they have in a field that has already seen development timelines shift dramatically?
In recent years we’ve seen biomarkers like ctDNA change the course of cancer studies, offering a shortcut to the market while offering a much clearer picture of what patient subgroups are likely to benefit from the slew of experimental therapies in the clinic. What new biomarkers are being hatched today? And what impact will they have in a field that has already seen development timelines shift dramatically?
A fireside chat and subsequent panel discussion with top analysts and drug makers to unpack the shifting regulatory landscape and other key issues across the life sciences industry.
Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what's at stake and what steps are being taken / can be taken / to prevent a devastating attack? And what are the best strategies for both big and small organizations.
Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what's at stake and what steps are being taken / can be taken / to prevent a devastating attack? And what are the best strategies for both big and small organizations.
A list of 10 high-profile mistakes in the industry, examined and analyzed
The Endpoints team will be covering all the major developments at this annual event. We’ll be matching the special report we do on the Monday of the science conference with a fireside chat and wrap it up with a panel of experts reviewing the most important data.
The Endpoints team will be covering all the major developments at this annual event. We’ll be matching the special report we do on the Monday of the science conference with a fireside chat and wrap it up with a panel of experts reviewing the most important data.
Exclusive insights from a group of hand-picked biotech CEOs and A-list investors, and more
Endpoints News will feature a prominent group of the top executives leading a new generation of European biotechs in an industry that has undergone major changes in recent years
Endpoints News reports on all the top news out of the world’s premier cell and gene therapy science conference. We will convene an online panel discussion on what topics grabbed the attention of the experts.